Investigation Report on China's Golimumab Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1008258|
|出版日期||內容資訊||英文 50 Pages
|中國的Golimumab市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Golimumab Market 2021-2025|
|出版日期: 2021年05月28日||內容資訊: 英文 50 Pages||
Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen Biologics BV. Its products were launched in China for the treatment of ankylosing spondylitis(AS)and rheumatoid arthritis (RA) in 2018. As of the first half of 2021, Janssen Biologics BV is the only manufacturer in the Chinese Golimumab market.
According to CRI's market research, the sales of Golimumab in the Chinese market have had a rapid upward trend from 2018 to 2020. The annual sales revenue in 2020 is CNY6.32 million, which increased over 10 times compared to that in 2018. The CAGR of Golimumab sales in the Chinese market in 2018-2020 is 242.6%. The main reason for the rapid growth is that Golimumab was included in China's medical insurance in 2019 and it entered the national medical insurance category B list in the field of rheumatism.
CRI analyzes that from 2021 to 2025,the sales will continue to increase due to its superior efficacy and low injection frequency. In addition, Golimumab will have a very broad market and the penetration rate of SIMPONI can be improved in the future. Therefore, the market share of Golimumab has the potential to increase, which will lead the sales volume to grow in the future.